EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A New Era in the Management of Hypertrophic Cardiomyopathy

Ana Perez-Asensio iD, Helena Llamas-Gomez iD, Ana Lara-Palomo, Alberto Villar-Ruiz, Cesar Jimenez-Mendez iD, Julian Palomino-Doza iD

Reviews in Cardiovascular Medicine · 30.10.2025 · 26 (10)

DOI: 10.31083/rcm44503 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 30.10.2025. Verfasst von Ana Perez-Asensio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital Universitario Puerta del Mar, 11007 Cadiz, Spain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation's Big Beat Challenge award to CureHeart.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac disease characterized by marked phenotypic variability. Recent advances in diagnosis and treatment have allowed a personalized approach to the treatment of this disease. Depending on the predominant phenotype, management can be tailored to address left ventricular outflow tract obstruction, heart failure, arrhythmia control, and/or sudden cardiac death prevention. This review highlights recent advances that have transformed the therapeutic landscape of HCM. Modern imaging techniques have improved sudden cardiac death risk stratification. The development of myosin inhibitors represents a paradigm shift in the treatment of symptomatic obstructive HCM. Invasive septal reduction techniques have also evolved, with novel approaches such as percutaneous intramyocardial septal radiofrequency ablation and transapical beating-heart septal myectomy. Finally, gene-targeted therapies including replacement, editing and silencing approaches, are emerging as promising strategies for HCM management.

Schlagwörter

Stichwörter der Autor:innen

gene therapyhypertrophic cardiomyopathymyosin inhibitorsseptal reduction therapiessudden cardiac death risk stratification

Autor:innen und Institutionen

  • Cardiology Department, Hospital Universitario Puerta del Mar, 11007 Cadiz, Spain.
  • Cardiology Department, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
  • Cardiology Department, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain.
  • Radcliffe Department of Medicine, Division of Cardiovascular Medicine, University of Oxford, OX1 2JD Oxford, UK.

ORCID-Profile: Ana Perez-Asensio, Helena Llamas-Gomez, Cesar Jimenez-Mendez, Julian Palomino-Doza

Förderung

  • British Heart Foundation's Big Beat Challenge award to CureHeart

Zitieren

APA

Perez-Asensio, A., Llamas-Gomez, H., Lara-Palomo, A., Villar-Ruiz, A., Jimenez-Mendez, C., & Palomino-Doza, J. (2025). A New Era in the Management of Hypertrophic Cardiomyopathy. Reviews in Cardiovascular Medicine, 26(10). https://doi.org/10.31083/rcm44503

Vancouver

Perez-Asensio A, Llamas-Gomez H, Lara-Palomo A, Villar-Ruiz A, Jimenez-Mendez C, Palomino-Doza J. A New Era in the Management of Hypertrophic Cardiomyopathy. Reviews in Cardiovascular Medicine. 2025;26(10). doi:10.31083/rcm44503

BibTeX
@article{PerezAsensio2025,
  author = {Perez-Asensio, Ana and Llamas-Gomez, Helena and Lara-Palomo, Ana and Villar-Ruiz, Alberto and Jimenez-Mendez, Cesar and Palomino-Doza, Julian},
  title = {A New Era in the Management of Hypertrophic Cardiomyopathy},
  journal = {Reviews in Cardiovascular Medicine},
  year = {2025},
  volume = {26},
  number = {10},
  doi = {10.31083/rcm44503}
}
Kostenlos starten →